Evaluation serum soluble interleukin 2 receptor with diagnosis and prognosis in canine solid tumour: 34 cases
Veterinary Medicine and Science · 2024
DOI: 10.1002/vms3.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Medicine and Science, 2024. Verfasst von Hyun NamKung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seo…. Hauptthemen laut MEDLINE: Dog Diseases, Receptors, Interleukin-2, Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background/Aim The soluble interleukin‐2 receptor (sIL‐2R) serve as a valuable biomarker for tumors in human patients, as its levels increase during the activation of T lymphocytes in clinical states such as inflammation, infection, and tumor. This study aimed to demonstrate that sIL‐2R levels can be also elevated in dogs with tumors and evaluate its applicability as a diagnostic and prognostic factor in canine cancer patients. Patients and Methods Serum was collected from 6 healthy dogs and 34 dogs with solid tumors. The concentration of sIL‐2R was measured using a commercial enzyme‐linked immunosorbent assay kit.
Results
The median sIL‐2R concentration was significantly higher in dogs with solid masses than in healthy dogs (117.3 vs 68.33 pg/ml, p = 0.016). The highest median sIL‐2R concentration was found in dogs with malignant tumors, followed by those with benign tumors, and healthy dogs (119.6 vs 93.74 vs 68.33 pg/ml, respectively). In dogs with malignant tumors, the mortality rate was significantly higher in the group with high sIL‐2R levels than in the group with low sIL‐2R levels. Dogs with solid tumors, particularly those with malignant tumors, had higher concentrations of sIL‐2R than healthy dogs. Among dogs with malignant tumors, a correlation between sIL‐2R concentration and mortality rate was confirmed.
Conclusion
Serum sIL‐2R levels may be used to detect malignant tumors and serve as a prognostic factor in dogs with malignant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
- Haemaru Small Animal Clinical Research Institute, Seongnam, Republic of Korea.
ORCID-Profile: Hyun NamKung, Su-Min Park, Ga-Hyun Lim, Min-Ok Ryu, Kyoung-Won Seo, Hwa-Young Youn
Zitieren
APA
NamKung, H., Park, S. M., Im, J. H., Lim, G. H., Ryu, M. O., Seo, K. W., & Youn, H. Y. (2024). Evaluation serum soluble interleukin 2 receptor with diagnosis and prognosis in canine solid tumour: 34 cases. Veterinary Medicine and Science. https://doi.org/10.1002/vms3.70033
Vancouver
NamKung H, Park SM, Im JH, Lim GH, Ryu MO, Seo KW, et al. Evaluation serum soluble interleukin 2 receptor with diagnosis and prognosis in canine solid tumour: 34 cases. Veterinary Medicine and Science. 2024. doi:10.1002/vms3.70033
BibTeX
@article{NamKung2024,
author = {NamKung, Hyun and Park, Su-Min and Im, Jae-Hyeon and Lim, Ga-Hyun and Ryu, Min-Ok and Seo, Kyoung-Won and Youn, Hwa-Young},
title = {Evaluation serum soluble interleukin 2 receptor with diagnosis and prognosis in canine solid tumour: 34 cases},
journal = {Veterinary Medicine and Science},
year = {2024},
doi = {10.1002/vms3.70033}
}
EUVIMED